Hormontherapie im Wandel der Zeit

Zusammenfassung

Trotz zahlreicher Studien in den letzten Jahren gilt weiterhin, dass ausschließlich Patientinnen mit klimakterischen Beschwerden und Therapiewunsch behandelt werden. Zur Primärprävention von Erkrankungen wie koronare Herzerkrankung, Osteoporose oder Depression ist eine peri- oder postmenopausale Hormontherapie nicht zu empfehlen. Das Risiko für Thrombosen, Lungenembolien und Schlaganfälle ist insbesondere bei älteren Frauen durch eine orale Hormontherapie erhöht. Bei jüngeren, frühmenopausalen Frauen ergibt sich ein deutlich günstigeres Nutzen-Risiko-Profil, sodass hier die Verordnung wieder großzügiger erfolgen kann. Vasomotorische Symptome werden systemisch, rein urogenitale lokal behandelt. Die Auswahl des Präparates erfolgt nach genauer Risikostratifizierung, in Abhängigkeit der Symptome und Vorliebe der Patientin. Eine transdermale Östrogen-Applikation – bei Frauen mit intaktem Uterus in Verbindung mit „natürlichem“ Progesteron – erscheint die beste Therapieoption bei Frauen mit erhöhten kardiovaskulären Risiken.

Abstract

Despite several studies in the last years, only women with menopausal symptoms who desire therapy are treated. There is still no recommendation for menopausale hormone therapy for primary prevention of diseases such as coronary artery disease, osteoporosis or depression. The risk of thrombosis, pulmonary embolism and stroke is elevated especially for elderly women with oral hormone therapy. Benefits may exceed risks in younger, early-menopausal women, for whom hormone therapy may be prescribed more liberally. Systemic hormone therapy is for vasomotor symptoms, local therapy for the genitourinary syndrome of menopause. Choice of formulation depends on the individual risk due to symptoms and favours of the patients. With moderate to high cardiovascular risk profile, a transdermal route of estrogen application – in women with an intact uterus in combination with micronized progesterone – seems to be the best option.

Schlüsselwörter

Hormontherapie - Östrogene - Menopause - Klimakterium

Keywords

hormone therapy - menopause - estrogen - climacteric

• Literatur

• 1 Avis NE, Crawford SL, Greendale G et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med 2015; 175: 531-539
• 2 Manson JE, Chlebowski RT, Stefanick ML et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA 2013; 310: 1353-1368
• 3 Schierbeck LL, Rejnmark L, Tofteng CL et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 2012; 345: e6409
• 4 Boardman HM, Hartley L, Eisinga A et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev 2015; 3: CD002229
• 5 Sweetland S, Beral V, Balkwill A et al. Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study. J Thromb Haemost 2012; 10: 2277-2286
• 6 Canonico M. Hormone therapy and risk of venous thromboembolism among postmenopausal women. Maturitas 2015; 82: 304-307
• 7 Harman SM, Black DM, Naftolin F et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med 2014; 161: 249-260
• 8 Stuenkel CA, Davis SR, Gompel A et al. Treatment of symptoms of the menopause: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2015; 100: 3975-4011
• 9 Pinkerton JV, Abraham L, Bushmakin AG et al. Evaluation of the efficacy and safety of bazedoxifene / conjugated estrogens for secondary outcomes including vasomotor symptoms in postmenopausal women by years since menopause in the Selective estrogens, Menopause and Response to Therapy (SMART) trials. J Womens Health (Larchmt) 2014; 23: 18-28
• 10 Pinkerton JV, Harvey JA, Lindsay R et al. Effects of bazedoxifene / conjugated estrogens on the endometrium and bone: a randomized trial. J Clin Endocrinol Metab 2014; 99: E189-198